This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

GM1 gangliosidosis — β-galactosidase deficiency / GLB1 / Infantile, juvenile, adult, Morquio B formsGM₁-강글리오시드증 (강글리오시드증 NOS)

Contents and key points
ItemDetails
A. Classification codesICD-10: E75.1 (other gangliosidosis)  |  Special Copayment Reduction: V117 (ultra-rare disease)
B. SynonymsGM₁ gangliosidosis, gangliosidosis NOS, β-galactosidase deficiency, GLB1 deficiency, Landing disease, mucopolysaccharidosis type IVB (Morquio B syndrome)
C. Adult onsetLikelihood of first onset in adulthood: yes (adult or chronic form) — cases have been reported in which variant combinations that retain some residual GLB1 enzyme activity first present in adulthood with extrapyramidal symptoms (parkinsonian syndrome, dystonia) or spinocerebellar ataxia.
1. History1964 Landing et al. describe infantile neurovisceral lipidosis → 1965 O'Brien confirms β-galactosidase deficiency → GLB1 gene cloned → Morquio B recognized as a variant of the same gene.
2. CausesGLB1 gene variants → deficiency of lysosomal acid β-galactosidase (GLB1) → lysosomal accumulation of GM1 ganglioside, keratan sulfate, and oligosaccharides.
3. GeneticsGLB1 gene (3p22.3), autosomal recessive, 16 exons. More than 200 pathogenic variants reported. Founder variants identified in Brazil, Korea, Malta, and Japan. Phenotype-genotype correlation present.
4. General epidemiologyAbout 1 per 100,000–200,000 births. Occurs in all ethnic groups worldwide. Higher frequency in some regions (southern Brazil, Malta). Reported cases in Korea.
5. PathophysiologyGLB1 deficiency → inability to break down GM1 ganglioside, galacto-oligosaccharides, and keratan sulfate → lysosomal accumulation in neurons and viscera → cellular dysfunction and death. Morquio B: driven by skeletal accumulation of keratan sulfate.
6. SymptomsInfantile form (type I): early developmental regression, exaggerated startle response, facial dysmorphism, hepatomegaly, cherry-red spot. Juvenile form (type II): onset at ages 3–10, motor regression, seizures. Adult form (type III): extrapyramidal signs and ataxia in adulthood. Morquio B: skeletal dysplasia.
7. SignsCherry-red spot (infantile form), hepatomegaly and splenomegaly, facial dysmorphism (coarse face, low-set ears, broad nose), MPS-like bone deformities, lumbar kyphosis, spondylolisthesis. Brain MRI: T2 hyperintensity in the basal ganglia and thalamus.
8. ScreeningDBS-based newborn screening by β-galactosidase activity measurement is at the research stage. With a family history, serum/leukocyte GLB1 activity + GLB1 gene analysis.
9. DiagnosisMarkedly reduced β-galactosidase activity in leukocytes and skin fibroblasts. Urine oligosaccharide and keratan sulfate analysis. Identification of biallelic pathogenic GLB1 variants. Skeletal radiographs, brain MRI.
10. TreatmentNo curative treatment (as of 2026). Symptomatic and supportive care. AAV gene therapy has shown efficacy preclinically, with preparation for clinical entry underway. Research on chaperone therapy (pharmacological chaperone). SRT research.
11. PrognosisInfantile form: most die at ages 2–4. Juvenile form: death at ages 5–15. Adult form and Morquio B: survival into adulthood possible, but with progressive disability.
12. PreventionCarrier testing, genetic counseling, prenatal diagnosis (CVS, amniocentesis), preimplantation genetic testing (PGT-M).
13. ReferencesLanding et al. 1964 and 9 other references

1. History

The clinical description of GM1 gangliosidosis began in 1964, when the American pediatrician Benjamin Landing and colleagues reported, under the name "infantile systemic gangliosidosis," a disease similar to GM2 gangliosidosis (Tay-Sachs disease) but additionally accompanied by visceral involvement and skeletal dysplasia. The disease was subsequently also called Landing disease. In 1965, John S. O'Brien and colleagues found that lysosomal acid β-D-galactosidase (acid β-galactosidase, β-Gal, the product of the GLB1 gene) activity was markedly reduced in liver tissue from patients with this disease, identifying the enzyme deficiency as the cause. With this discovery, the disease was renamed "GM1 gangliosidosis," and GM1 ganglioside was confirmed as the main accumulating substrate.

In the 1960s–70s, classification by clinical form was made. The infantile form (type 1), juvenile form (type 2), and adult form (type 3) were distinguished, and subsequently Morquio B syndrome (mucopolysaccharidosis type IVB), which shows mainly skeletal dysplasia and mild neurological involvement, was recognized as a variant form of the same disease caused by the same deficiency of the GLB1 gene. In Morquio B, because GLB1 cleaves the terminal β-galactosidase site of keratan sulfate, keratan sulfate accumulates mainly in the skeleton when GLB1 is deficient, and bone dysplasia is the main clinical picture.

The molecular basis was established in the 1990s. As the GLB1 gene (3p22.3) was cloned and many pathogenic variants were identified, research on phenotype-genotype correlation became active. Since the 2000s, founder variants have been identified in southern Brazil, Malta, Japan, and elsewhere, and as AAV vector-based gene therapy has shown outstanding efficacy in mouse, cat, and cattle models, foundational research for entry into clinical trials has been accumulating. Pharmacological chaperone therapy is also being studied in variant combinations with potential for GLB1 protein stabilization.


2. Causes

GM1 gangliosidosis occurs when pathogenic variants arise in both alleles of the GLB1 gene, resulting in deficient activity of the lysosomal enzyme acid β-D-galactosidase (acid β-galactosidase, EC 3.2.1.23). The GLB1 enzyme cleaves the terminal β-galactose residue of GM1 ganglioside at the acidic pH of the lysosome, converting it to GM2. GLB1 also cleaves the terminal β-galactose residues of keratan sulfate, lactosylceramide, and oligosaccharides (galacto-oligosaccharides derived from glycoproteins). Therefore, in GLB1 deficiency, GM1 ganglioside, keratan sulfate, and galacto-oligosaccharides accumulate in lysosomes.

GM1 ganglioside is an important component of neuronal membranes and plays an essential role in neural development and signal transduction. When GM1 accumulates in neuronal lysosomes because of GLB1 deficiency, lysosomal dysfunction, cellular stress, and neuronal death are induced, causing progressive neurodegeneration. Accumulation of keratan sulfate occurs mainly in the skeleton (cartilage and bone) and causes the skeletal dysplasia seen in Morquio B. Galacto-oligosaccharides are excreted in the urine and used as a diagnostic marker.

The spectrum of GLB1 gene variants is broad, and more than 200 pathogenic variants have been reported to date. In general, lower residual enzyme activity (less than 1%) is associated with the severe infantile phenotype, some residual activity (1–5%) with the juvenile form, and 5% or more with the adult form or Morquio B. However, phenotypic differences between individuals exist even with the same variant combination.


3. Genetics

The GLB1 gene is located on the short arm of chromosome 3 (3p22.3) and consists of 16 exons. The total genomic length is about 62 kb, and the translated precursor protein has 677 amino acids. The mature GLB1 protein forms a multienzyme complex in the lysosome, which includes, in addition to GLB1, neuraminidase-1 (NEU1) and protective protein/cathepsin A (PPCA). Because PPCA protects GLB1 and NEU1 from proteolysis in the lysosome, GLB1 activity can also be secondarily reduced in PPCA deficiency (sialidosis, galactosialidosis).

The mode of inheritance is autosomal recessive. Of the more than 200 pathogenic GLB1 variants reported to date, missense variants are the most common, followed by splicing variants, deletions, and insertions. Representative founder variants reported include R59H (p.Arg59His) in the population of Portuguese descent in southern Brazil, R482H (p.Arg482His) in Japan, and I51T (p.Ile51Thr) in Malta. A predominance of particular variants has also been reported in Korea.

The fact that Morquio B and the neurological forms of GM1 gangliosidosis (types I–III) arise from variants in the same GLB1 gene initially seemed paradoxical. However, research shows that the GM1 ganglioside-degrading activity and the keratan sulfate-degrading activity of the GLB1 enzyme depend on different substrate-binding domains, so the two activities can be selectively affected depending on the specific variant. Therefore, the skeletal dysplasia-predominant form (Morquio B) is expressed in variant combinations in which keratan sulfate degradation efficiency is mainly impaired and some residual GM1-degrading activity is maintained.

Carrier status is determined by confirming that leukocyte or serum GLB1 activity is at 40–60% of normal or by detecting a heterozygous GLB1 gene variant. Carrier determination by enzyme activity alone is sometimes ambiguous, so molecular confirmation is recommended. In genetic counseling, the 25% recurrence risk for siblings is communicated, and options of prenatal diagnosis and PGT-M are offered.


4. General epidemiology

GM1 gangliosidosis is a rare disease with an estimated frequency of about 1 per 100,000–200,000 births worldwide. It occurs in all ethnic groups, but relatively high prevalence due to founder mutations has been reported in certain regions. A concentration of infantile-form patients has been reported in the population of Portuguese descent in southern Brazil, and a high frequency of Morquio B is known on the Mediterranean island of Malta. In Japan, relatively many patients with the adult and juvenile forms have been reported, and a founder variant (R482H) has been identified as the cause.

The distribution by clinical form is estimated at about 50–60% infantile (type I), about 20–30% juvenile (type II), about 10–15% adult (type III), and about 5–10% Morquio B, but this varies with diagnostic access and reporting systems. There is no sex difference (autosomal recessive). The proportion of de novo mutations without a family history is unknown but is presumed to be considerable. Cases have been reported in Korea, and it is designated as an ultra-rare disease (Special Copayment Reduction V117).

The number of prevalent patients worldwide is estimated in the thousands, but precise statistics are lacking. As expanded newborn screening is introduced in some countries, the proportion of early diagnoses is expected to increase.


5. Pathophysiology

The lysosomal GLB1 enzyme cleaves the terminal Galβ(1→3) or Galβ(1→4) linkage of GM1 ganglioside, converting it to GM2. In GLB1 deficiency, this degradation reaction is blocked, and GM1 ganglioside accumulates in lysosomes. GM1 is normally abundant in neuronal membranes and is an important glycolipid involved in cell signaling, neurotrophic factor receptor function, and neuronal differentiation. Excessive accumulation of GM1 in lysosomes causes lysosomal membrane damage, disruption of autophagy due to lysosomal storage burden, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction. As a result of this cascade, apoptosis and necrosis are induced in neurons.

GM1 accumulation in neurons forms giant lysosomes in brain neurons, which are observed on electron microscopy as membranous cytoplasmic bodies (MCBs). Cortical neurons, the basal ganglia, thalamus, cerebellum, and spinal motor neurons are preferentially affected. In the infantile form, GM1 accumulation occurs in almost all regions of the brain, causing widespread neurodegeneration, whereas in the adult form, the basal ganglia and cerebellar circuits tend to be selectively more affected.

Keratan sulfate (KS) is a proteoglycan component of chondrocytes, bone, and the cornea. Because GLB1 is required to remove the terminal β-galactose residues of KS chains, in deficiency KS accumulates in the skeleton (especially cartilage, spine, and long bones), causing abnormal bone development. This is the mechanism by which skeletal dysplasia appears as the main symptom in Morquio B. Galacto-oligosaccharides (complex sugars with terminal galactose) are also excreted in the urine and detected by urine oligosaccharide testing (TLC, HPLC).

The fact that GLB1 functions as a member of a multienzyme complex (NEU1, PPCA) is also pathophysiologically important. Just as GLB1 and NEU1 are secondarily impaired in galactosialidosis, which is PPCA deficiency, a secondary reduction in NEU1 activity is also observed in patients with GLB1 deficiency, which can further complicate the accumulating substrates.


6. Symptoms

The clinical symptoms of GM1 gangliosidosis are classified into four main clinical forms according to residual GLB1 enzyme activity and the main sites of accumulation of GM1 ganglioside and keratan sulfate.

Infantile form (type I, pediatric infantile form): the most severe type, with symptoms appearing at birth or within the first few months of life. Some infants show hypotonia, feeding difficulties, and reduced responsiveness from birth. Developmental arrest or regression begins at 3–6 months, followed by an exaggerated startle response, irritability, and visual impairment. Unlike GM2 gangliosidosis, facial dysmorphism (coarse facies) is present—coarse facial features reminiscent of mucopolysaccharidosis (MPS), low-set ears, a flat nose, thick gums, and macroglossia—reflecting connective tissue accumulation of keratan sulfate and galacto-oligosaccharides. Hepatomegaly and splenomegaly are almost always present. Edema of the hands and feet and skin hyperpigmentation are sometimes observed. Seizures are more common after progression than early in the disease. Neurodegeneration of the brain and spinal cord progresses rapidly, with maximal functional regression by 6–12 months.

Juvenile form (type II): after normal development at ages 1–3, impaired motor coordination, regression of language development, and spastic quadriplegia gradually appear. Seizures are present, and facial dysmorphism and visceromegaly are milder than in the infantile form or absent. The cherry-red spot is observed in about 50% of the infantile form but is rare in the juvenile form.

Adult form (type III, chronic form): begins in late adolescence or early adulthood with extrapyramidal symptoms—progressive dystonia, parkinsonian syndrome, cerebellar ataxia. Cognitive decline is mild and progresses slowly, and there is no visceromegaly. The cherry-red spot is also rare. The adult form can be misdiagnosed as Parkinson disease, multiple system atrophy (MSA), spinocerebellar ataxia, and so on, and diagnosis is sometimes delayed because it is not suspected on gene panel testing.

Morquio B (mucopolysaccharidosis type IVB): neurological involvement is absent or mild, and skeletal dysplasia is the main clinical picture. Characteristic features include short stature, thoracolumbar kyphosis, joint hyperextensibility, corneal clouding, abnormal dental enamel formation, platyspondyly, and odontoid hypoplasia. Cervical spinal cord compression due to odontoid hypoplasia (atlantoaxial instability) is an important complication.


7. Signs

Fundus examination: the cherry-red spot is observed in about 50% of the infantile form and reflects GM1 accumulation in macular ganglion cells. Vision is lost as optic atrophy progresses.

Facial and head and neck dysmorphism: mucopolysaccharidosis-like facial dysmorphism (coarse face, thick lips and gums, low-set ears, short philtrum, flat nose, etc.) is clearly observed in the infantile form. Macrocephaly and frontal bossing may be present.

Musculoskeletal findings: in the infantile and juvenile forms, spastic quadriplegia, hyperreflexia, a positive Babinski sign, and later conversion from hypotonia to spasticity are observed. In Morquio B, short stature, thoracolumbar kyphosis and lordosis abnormalities, thoracic deformity, joint hyperextensibility, and corneal clouding are characteristic. Radiographs show dysostosis multiplex, including spondylolisthesis, platyspondyly, dysplasia of the radius and ulna, and dysplasia of the long bones.

Visceral signs: hepatomegaly and splenomegaly are confirmed by abdominal palpation or ultrasound in most patients with the infantile form. Lysosomal vacuolization in lymphocytes and monocytes is observed on peripheral blood smear.

Brain MRI: T2/FLAIR hyperintense lesions in the basal ganglia (caudate nucleus, putamen) and thalamus are characteristic, and in the infantile form, diffuse increased T2 signal in the cerebral white matter and generalized brain atrophy progress. In the adult form, focal signal changes in the basal ganglia are prominent.

Urine testing: galacto-oligosaccharide bands are increased on urine oligosaccharide TLC (thin-layer chromatography), and keratan sulfate analysis shows elevation.

Electrophysiological testing: EEG shows generalized slowing, epileptiform discharges, and so on, and conduction delays may appear on auditory evoked potentials and visual evoked potentials.


8. Screening

Standard newborn screening for GM1 gangliosidosis has not yet been introduced in most countries. However, DBS (dried blood spot)-based measurement of β-galactosidase activity is technically possible, and some research institutions and some US states are studying and reviewing its inclusion in expanded newborn screening panels.

DBS enzyme activity measurement: methods have been developed to measure GLB1 enzyme activity from a DBS obtained by neonatal heel-prick using a fluorescent substrate (4-methylumbelliferyl-β-D-galactopyranoside, 4-MUG) or substrate analysis based on tandem mass spectrometry (LC-MS/MS). However, this test alone cannot readily differentiate galactosialidosis (PPCA deficiency), so additional testing is needed.

Family history-based screening: carrier status is determined in siblings and parents of patients by leukocyte GLB1 activity measurement and GLB1 gene analysis, and in case of pregnancy, they are immediately referred for prenatal diagnosis. In regions with a high frequency of founder variants, such as southern Brazil, targeted population screening for specific high-risk variants may be considered.

Clinical screening clues: in the infantile form, the combination of a cherry-red spot, coarse facial dysmorphism, and hepatosplenomegaly is a strong clinical clue that should prompt immediate enzyme testing and urine oligosaccharide testing. In the adult form, GM1 gangliosidosis should be included in the differential diagnosis of dystonia or cerebellar ataxia of unknown cause.


9. Diagnosis

GM1 gangliosidosis is confirmed by the combination of enzyme activity measurement and GLB1 gene analysis.

Enzyme activity measurement: acid β-galactosidase activity is measured in leukocytes or skin fibroblasts by the fluorescent substrate method (4-MUG substrate). In patients, activity is markedly reduced to less than 1–5% of normal. However, because GLB1 activity can also be secondarily reduced in galactosialidosis, which is PPCA deficiency, neuraminidase-1 (NEU1) activity is measured at the same time for differentiation. In galactosialidosis, both GLB1 and NEU1 are reduced, whereas in GM1 gangliosidosis, only GLB1 is reduced.

Urine oligosaccharide and keratan sulfate testing: increased galacto-oligosaccharides are confirmed on urine oligosaccharide TLC (thin-layer chromatography) or HPLC. Quantification of urine keratan sulfate (KS) is useful as an aid to the diagnosis of Morquio B.

Molecular genetic testing: pathogenic variants on both alleles are identified by next-generation sequencing (NGS) or Sanger sequencing of the GLB1 gene. Large deletions and rearrangements are detected by MLPA. Genetic testing is essential for phenotype prediction, genetic counseling, testing of carrier family members, and prenatal diagnosis.

Imaging studies: brain MRI shows T2 hyperintensity in the basal ganglia and thalamus, white matter abnormalities, brain atrophy, and so on. In Morquio B, a whole-body skeletal survey shows dysostosis multiplex, including platyspondyly, odontoid hypoplasia, and dysplasia of the long bones. Cervical spine MRI is essential for assessing atlantoaxial instability and cervical cord compression.

Prenatal diagnosis: GLB1 enzyme activity measurement or direct detection of the familial variant is possible in fetal cells obtained by CVS (11–14 weeks) or amniocentesis (15–20 weeks). Implantation of affected embryos can also be prevented by PGT-M.


10. Treatment

As of 2026, there is no established curative treatment for GM1 gangliosidosis. Treatment is based on symptomatic and supportive care and management of complications, and the following investigational treatment strategies are under development.

Symptomatic and supportive care: administration of anticonvulsants for seizure control is central. For dysphagia and malnutrition, nutrition is provided by nasogastric tube or gastrostomy tube (PEG). When airway protection declines, aspiration prevention measures and respiratory support (NIV, mechanical ventilation) are needed. Physical, occupational, and speech therapy support maintenance of function. In Morquio B, orthopedic procedures (spinal fixation, cervical fusion) are important for preventing atlantoaxial instability and spinal cord compression.

AAV gene therapy (investigational): GLB1 gene delivery using AAV9 or AAVrh10 vectors showed outstanding effects in mouse, cat, and cattle models of GM1 gangliosidosis, reducing GM1 accumulation, improving neurological lesions, and prolonging survival. Intra-cerebrospinal fluid administration (intracerebroventricular, intrathecal), intravenous administration, and combined administration have been explored. Since the early 2020s, phase 1/2 human clinical trials have begun at some institutions, and early results are attracting attention.

Pharmacological chaperone therapy: small-molecule drugs that can stabilize misfolded GLB1 protein (e.g., N-octyl-4-epi-β-valienamine, NOEV; 1-deoxygalactonojirimycin derivatives) have shown restoration of GLB1 activity in cell and animal models. They may be effective in variant combinations with some residual enzyme activity (mainly missense), and clinical research is underway.

Substrate reduction therapy (SRT): because glucosylceramide synthesis inhibitors such as miglustat and eliglustat do not target the upstream GM1 ganglioside synthesis pathway, there is currently no approved agent for direct SRT for GM1. ST3Gal5 inhibitors and others that inhibit the early steps of GM1 synthesis are being explored at the preclinical stage.


11. Prognosis

The prognosis of GM1 gangliosidosis differs greatly by clinical form. In the infantile form (type I), complete developmental regression progresses rapidly, and most die before ages 2–4 of respiratory failure, aspiration pneumonia, status epilepticus, and so on. Intensive supportive care can extend survival somewhat but does not change the fundamental course. In the juvenile form (type II), neurological decline progresses over 5–15 years after onset, with death in late adolescence to early adulthood. In the adult form (type III), survival for decades is possible, but gradual extrapyramidal and cerebellar decline limits quality of life. In Morquio B, neurological involvement is mild and life span is relatively close to normal, but skeletal complications (cervical instability, respiratory restriction, joint deformities) cause functional limitations. Cervical cord compression due to atlantoaxial instability is a risk factor for sudden quadriplegia or respiratory failure.

Clinical trials of AAV gene therapy to improve prognosis are underway, and the therapeutic effect is expected to be greater in patients at the presymptomatic or early symptomatic stage. Expansion of newborn screening and the development of gene therapy have the potential to fundamentally change prognosis in the future.


12. Prevention

The core of prevention of GM1 gangliosidosis is secondary prevention through genetic counseling, carrier testing, prenatal diagnosis, and preimplantation genetic testing.

Genetic counseling: after a patient is diagnosed, the autosomal recessive inheritance pattern and recurrence risk (25%) are explained to parents and siblings, and carrier testing is recommended for extended family members. Carrier couples planning pregnancy are offered the options of prenatal diagnosis and PGT-M.

Prenatal diagnosis: fetal diagnosis is performed by CVS (11–14 weeks) or amniocentesis (15–20 weeks) based on the GLB1 variant or GLB1 enzyme deficiency identified in the family. Enzyme activity measurement and molecular variant detection are performed together.

Preimplantation genetic testing (PGT-M): a method of selecting and excluding affected embryos in conjunction with in vitro fertilization, preventing affected pregnancies altogether. Possible when GLB1 variants have been identified in both parents.

Population screening: in populations with a high frequency of founder variants, such as southern Brazil, Malta, and Japan, preconception carrier screening may be considered at the health system level. Universal screening of the general population is currently not recommended.

If newborn screening is expanded in the future, it is expected to contribute to primary prevention (prevention of neurological damage) through early detection and early application of gene therapy.


13. References

  1. Landing BH, Silverman FN, Craig JM, et al. Familial neurovisceral lipidosis. Am J Dis Child. 1964;108:503-522. PMID: 14226440.
  2. O'Brien JS, Stern MB, Landing BH, et al. Generalized gangliosidosis: another inborn error of ganglioside metabolism? Am J Dis Child. 1965;109:338-346. PMID: 14253668.
  3. Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94(4):391-396. PMID: 18524657. DOI: 10.1016/j.ymgme.2008.04.012.
  4. Caciotti A, Garman SC, Rivera-Colón Y, et al. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta. 2011;1812(7):782-790. PMID: 21443952.
  5. Nicoli ER, Annunziata I, D'Azzo A, et al. GM1 gangliosidosis — new insights into an old disease. Int J Mol Sci. 2021;22(8):3888. PMID: 33918546. DOI: 10.3390/ijms22083888.
  6. Spampanato C, De Leonibus E, Dama P, et al. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther. 2011;19(5):860-869. PMID: 21364538.
  7. Woodley E, Bhatt H, Bhatt U, et al. A single dose of AAV9-GLB1 achieves long-term correction of neurological disease in GM1 gangliosidosis mice. Mol Ther Methods Clin Dev. 2022;25:202-216. PMID: 35402633. DOI: 10.1016/j.omtm.2022.03.010.
  8. Sano R, Tessitore A, Ingrassia A, d'Azzo A. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 2005;106(7):2259-2268. PMID: 15956284.
  9. Santamaria R, Chabás A, Coll MJ, et al. Twenty-one novel mutations in the GLB1 gene identified in a large group of GM1-gangliosidosis and Morquio B patients. Hum Mutat. 2006;27(10):1060. PMID: 16941485.
  10. Kato Z, Ikeda R, Sakamoto S, et al. Molecular characterization of amino acid substitutions in the beta-galactosidase gene causing GM1-gangliosidosis and Morquio B disease. Int J Mol Sci. 2018;19(6):1566. PMID: 29882770. DOI: 10.3390/ijms19061566.